As such, it is possible that CYP3A5 rs776746C allele carriers may derive greater benefit from antihypertensive drugs that are CYP3A5 substrates, which also results in reduced occurrence of hypertension-related adverse outcomes such as CKD. This evidence concerns the gene CYP3A5 and hypertensive disorder.